Stockscreener 앱 받기
42.10
0.19%
0.08
시장 영업 전:
41.30
-0.80
-1.90%
전일 마감가:
$42.02
열려 있는:
$41.87
하루 거래량:
698.48K
Relative Volume:
0.83
시가총액:
$2.45B
수익:
$899.11M
순이익/손실:
$145.62M
주가수익비율:
16.96
EPS:
2.4829
순현금흐름:
$322.54M
1주 성능:
+1.35%
1개월 성능:
+10.35%
6개월 성능:
+51.88%
1년 성능:
+29.38%
1일 변동 폭
$41.20
$42.52
1주일 범위
$40.94
$43.27
52주 변동 폭
$25.52
$43.49
하모니 바이오 Stock (HRMY) Company Profile
명칭
Harmony Biosciences Holdings Inc
전화
(484) 539-9800
주소
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
42.10 | 2.42B | 899.11M | 145.62M | 322.54M | 2.4829 |
VRTX
Vertex Pharmaceuticals Inc
|
510.72 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
798.17 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
172.94 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
988.20 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.67 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
하모니 바이오 Stock (HRMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-23 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2026-02-23 | 다운그레이드 | Truist | Buy → Hold |
| 2026-02-11 | 재개 | UBS | Neutral |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-17 | 개시 | H.C. Wainwright | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-10 | 개시 | UBS | Buy |
| 2024-06-21 | 개시 | Citigroup | Buy |
| 2024-01-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-09-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2023-09-07 | 개시 | Berenberg | Buy |
| 2023-04-20 | 개시 | BofA Securities | Neutral |
| 2022-10-14 | 업그레이드 | Janney | Neutral → Buy |
| 2022-10-14 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-04 | 개시 | Raymond James | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-03-29 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-14 | 개시 | Goldman | Neutral |
| 2020-09-14 | 개시 | Jefferies | Buy |
| 2020-09-14 | 개시 | Piper Sandler | Overweight |
모두보기
하모니 바이오 주식(HRMY)의 최신 뉴스
HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say? - Stocktwits
(HRMY) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
HRMY: Pipeline expansion, BP-205 progress, and BD deals drive next phase of growth - TradingView
Engaging In Options Activity, Kumar Budur Exercises Options Valued At $262K In Harmony Biosciences Hldgs - Benzinga
Harmony Biosciences CMO Kumar Budur Executes Stock Sales and Option Exercises in Early September 2026 - Kalkine Media
Harmony Biosciences (NASDAQ: HRMY) CMO exercises 22,954 options, sells shares under trading plan - Stock Titan
Harmony Biosciences (NASDAQ: HRMY) officer lines up a seven-figure stock sale - Stock Titan
Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now - Eastern Progress
Harmony Biosciences Announces Preliminary Q2 Revenue, CFO Transition — Says Executive’s Departure Not Due To Any Disagreement - Stocktwits
Harmony Biosciences stock holds near USD 41.86 - AD HOC NEWS
Harmony Biosciences (HRMY) executive to sell about $230K in stock - Stock Titan
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report? - Yahoo Finance
Harmony Biosciences to Present Encore EPX-100 Data from ARGUS Study at 16th European Epilepsy Congress - Quiver Quantitative
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress - Yahoo Finance
Harmony Biosciences stock hits 52-week high at $42.70 By Investing.com - Investing.com South Africa
Top 5 US Stocks To Buy In September 2026 - investing.com
Harmony Biosciences stock hits 52-week high at $42.70 - Investing.com
Precision Trading with Harmony Biosciences Holdings Inc. (HRMY) Risk Zones - Stock Traders Daily
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference - Investing News Network
This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
HRMY Initiates Coverage On Wolfe Research -- Rating Set to Outpe - GuruFocus
Wolfe Research initiates Harmony Biosciences stock at Outperform - Investing.com
Wolfe Research initiates Harmony Biosciences stock at Outperform By Investing.com - Investing.com Canada
Virtus Advisers LLC Makes New Investment in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Tieton Capital Management LLC Takes Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Denali Advisors LLC Purchases 29,700 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Stephen M. Mollichella Net Worth (2026) - GuruFocus
Aurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Did Strong Q2 Earnings and Completed Buybacks Just Shift Harmony Biosciences' (HRMY) Investment Narrative? - simplywall.st
Chase Investment Counsel Corp Takes $1.82 Million Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline - MarketBeat
HRMY: Record WAKIX sales drive CNS pipeline progress, with BP-205 and new pitolisant forms advancing - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Zacks Research Downgrades Harmony Biosciences (NASDAQ:HRMY) to Hold - MarketBeat
Harmony Biosciences Holdings, I (HRMY) Stock Forecasts - Yahoo Finance
Harmony Sets Investor Appearance as CNS Strategy Advances - MyChesCo
Hennion & Walsh Asset Management Inc. Decreases Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings (HRMY) Stock Analysis: Exploring an 18% Potential Upside with Strong Revenue Growth - DirectorsTalk Interviews
Harmony Biosciences Holdings, Inc. $HRMY Shares Sold by Janus Henderson Group PLC - MarketBeat
(HRMY) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Why Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Surge And Pipeline Progress - Sahm
Harmony Profit Jumps as WAKIX Revenue Climbs 30% - MyChesCo
Harmony Biosciences (NASDAQ:HRMY) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Jump And Pipeline ProgressWhat's Changed - Yahoo Finance
Harmony Biosciences (NASDAQ: HRMY) holder to sell 700,883 shares - Stock Titan
Harmony Biosciences Holdings, Inc. Just Recorded A 34% EPS Beat: Here's What Analysts Are Forecasting Next - Moomoo
First Trust Advisors LP Sells 50,805 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings Inc (HRMY) Stock News Today - TradingKey
Harmony Biosciences Holdings Inc (HRMY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
하모니 바이오 (HRMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
하모니 바이오 주식 (HRMY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 16 '26 |
Option Exercise |
30.48 |
1,800 |
54,864 |
14,915 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 17 '26 |
Option Exercise |
30.48 |
800 |
24,384 |
13,915 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 18 '26 |
Sale |
43.05 |
35,852 |
1,543,590 |
13,115 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 16 '26 |
Sale |
43.01 |
1,800 |
77,426 |
13,115 |
| Budur Kumar | CHIEF MEDICAL OFFICER |
Sep 17 '26 |
Sale |
43.00 |
800 |
34,400 |
13,115 |
0.05%
1.96%
자본화:
|
볼륨(24시간):